Zhongli Luo

Prof. Dr. Zhongli Luo


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Molecules
Verified
Journal Article
Open access
PDF file
JCJialei Chen
Jialei Chen
JLJing Luo
Jing Luo
DSDi Su
Di Su
NLNa Lu
Na Lu
ZLZhongli Luo
Zhongli Luo
ZLZhongli Luo
Zhongli Luo
Self-assembled peptide-based nanobiomaterials exhibit promising prospects for drug delivery applications owing to their commendable biocompatibility and biodegradability, facile tissue uptake and utilization, and minimal or negligible unexpected toxicity. TFF3 is an active peptide autonomously secreted by gastric mucosal cells, possessing multiple biological functions. It acts on the surface of the gastric mucosa, facilitating the repair process of gastric mucosal damage. However, when used as a drug, TFF3 faces significant challenges, including short retention time in the gastric mucosal cavity and deactivation due to degradation by stomach acid. In response to this challenge, we developed a self−assembled short peptide hydrogel, Rqdl10, designed as a delivery vehicle for TFF3. Our investigation encompasses an assessment of its properties, biocompatibility, controlled release of TFF3, and the mechanism underlying the promotion of gastric mucosal injury repair. Congo red/aniline blue staining revealed that Rqdl10 promptly self-assembled in PBS, forming hydrogels. Circular dichroism spectra indicated the presence of a stable β-sheet secondary structure in the Rqdl10 hydrogel. Cryo-scanning electron microscopy and atomic force microscopy observations demonstrated that the Rqdl10 formed vesicle-like structures in the PBS, which were interconnected to construct a three-dimensional nanostructure. Moreover, the Rqdl10 hydrogel exhibited outstanding biocompatibility and could sustainably and slowly release TFF3. The utilization of the Rqdl10 hydrogel as a carrier for TFF3 substantially augmented its proliferative and migratory capabilities, while concurrently bolstering its anti-inflammatory and anti-apoptotic attributes following gastric mucosal injury. Our findings underscore the immense potential of the self-assembled peptide hydrogel Rqdl10 for biomedical applications, promising significant contributions to healthcare science.

27 May 2025 in Gels
Verified
Journal Article
Open access
PDF file
YGYu Gao
Yu Gao
DSDi Su
Di Su
ZLZhongli Luo
Zhongli Luo
ZLZhongli Luo
Zhongli Luo
XLXuemei Lin
Xuemei Lin
In recent years, the incidence of colorectal cancer has been increasing annually. During the research on tumor treatment strategies, the translation of fundamental research findings into clinical applications has often been constrained by the limitations of existing tumor models, with few breakthroughs achieved to date. Therefore, our objective is to explore the feasibility of utilizing self-assembling short peptides (SAPs) to construct a three-dimensional (3D) culture system for colorectal adenocarcinoma cells for anticancer drug screening. By characterizing the physicochemical properties and biocompatibility of SAP SCIOBIO III, we demonstrated that it can rapidly self-assemble into a nanofibrous scaffold under ionic triggers, supporting 3D cell culture. Subsequently, anticancer drug sensitivity tests were conducted on both 2D and 3D culture systems of colorectal adenocarcinoma cells. The results indicate that SCIOBIO III can mimic the extracellular matrix and serves as an ideal scaffold for constructing a 3D cell culture microenvironment. We successfully established a 3D culture model for colorectal adenocarcinoma cells and effectively screened anticancer drugs, which holds promise for advancing the development of personalized anticancer drug screening technologies.

Verified
Journal Article
Open access
PDF file
GLGuicen Liu
Guicen Liu
QLQichen Liu
Qichen Liu
ZLZhongli Luo
Zhongli Luo
RLRuyue Luo
Ruyue Luo
YWYuan Wan
Yuan Wan
ZLZhongli Luo
Zhongli Luo
Clear cell renal cell carcinoma (ccRCC) is the most common kidney malignancy, with a poor prognosis for advanced-stage patients. Identifying key biomarkers involved in tumor progression is crucial for improving treatment outcomes. In this study, we employed an integrated approach combining single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing (bulk RNA-seq) to identify biomarkers associated with ccRCC progression and prognosis. Single-cell transcriptomic data were obtained from publicly available datasets, and genes related to tumor progression were screened using Monocle2. Bulk RNA-seq data for ccRCC were retrieved from The Cancer Genome Atlas (TCGA) and integrated with scRNA-seq data to explore tumor heterogeneity. We identified 3 beta-hydroxy steroid dehydrogenase type 7 (HSD3B7) as a candidate biomarker for ccRCC, associated with poor overall survival, disease-specific survival, and progression-free interval. Elevated HSD3B7 expression correlated with aggressive clinical features such as advanced TNM stages, histologic grades, and metastasis. Functional studies demonstrated that HSD3B7 promotes cell proliferation, migration, and invasion in vitro, while its silencing significantly inhibits tumor growth in vivo. Our findings reveal that HSD3B7 is a novel biomarker for ccRCC, providing insights into its role in tumor progression and potential as a target for therapy. This study highlights the value of integrating scRNA-seq and bulk RNA-seq data to uncover key regulators of tumor biology and lays the foundation for developing personalized therapeutic strategies for ccRCC patients.